No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
1-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride |
Piperazine |
D00807, D01393, D02127, D02145, D05486, D06224 |
- |
- |
[1] 58 |
2 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
[14] 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
3 |
Adenosine |
Adenosine |
D00045 |
[4] ADORA1, ADORA2A, ADORA2B, ADORA3 |
[12] Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[3] 13, 58, 65 |
4 |
Alcohol |
Ethanol |
D00068, D02798, D04855, D06542 |
- |
- |
[4] 13, 58, 279, 298 |
5 |
Antiarrhythmic drugs |
- |
- |
- |
- |
[1] 58 |
6 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
[1] HMGCR |
[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
[17] 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
7 |
Bluefish |
Bluefish |
- |
- |
- |
[1] 58 |
8 |
Bnp blood sample test |
- |
- |
- |
- |
[1] 58 |
9 |
Candesartan |
Candesartan |
D00522 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[2] 58, 67 |
10 |
Carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
[8] 5, 13, 58, 96, 97, 265, 298, 316 |
11 |
Cas name: 1,4-benzoxazepin-5(2h)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] iupac name: 4-(pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2h)-one |
- |
- |
- |
- |
[1] 58 |
12 |
Cas name: 1,4-benzoxazepin-5(2h)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] iupac name: 4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2h)-one |
- |
- |
- |
- |
[1] 58 |
13 |
Ck-3773274 |
- |
- |
- |
- |
[1] 58 |
14 |
Cyclosporine |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[33] 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
15 |
Cyclosporine a |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[8] 19, 20, 36, 49, 53, 58, 60, 234 |
16 |
Diltiazem |
Diltiazem |
D00616, D03830, D07845 |
[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S |
[34] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[3] 58, 86, 130 |
17 |
Diovan |
Valsartan |
D00400 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[1] 58 |
18 |
Diovan 160 mg |
Valsartan |
D00400 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[1] 58 |
19 |
Diovan 40 mg |
Valsartan |
D00400 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[1] 58 |
20 |
Diovan 80 mg |
Valsartan |
D00400 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[1] 58 |
21 |
Dobutamine |
Dobutamine |
D00632, D03879, D03880, D03881 |
[1] ADRB1 |
[10] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
[3] 57, 58, 215 |
22 |
Echo and myocardial contrast echocardiography perfusion imaging |
- |
- |
- |
- |
[1] 58 |
23 |
Endothelial function biomarkers |
- |
- |
- |
- |
[1] 58 |
24 |
Gadolinium |
Gadolinium |
- |
- |
- |
[6] 13, 34, 46, 58, 65, 305 |
25 |
Gs-6615 3 mg pink |
- |
- |
- |
- |
[1] 58 |
26 |
Gs-6615 3 mg white |
- |
- |
- |
- |
[1] 58 |
27 |
Gs-6615 6 mg white |
- |
- |
- |
- |
[1] 58 |
28 |
Gutron |
Midodrine |
D01307, D08220 |
[3] ADRA1A, ADRA1B, ADRA1D |
[7] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[1] 58 |
29 |
Gutron 2,5mg |
Midodrine |
D01307, D08220 |
[3] ADRA1A, ADRA1B, ADRA1D |
[7] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[1] 58 |
30 |
Gutron 5mg |
Midodrine |
D01307, D08220 |
[3] ADRA1A, ADRA1B, ADRA1D |
[7] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[1] 58 |
31 |
Hyperpolarized 13c-pyruvate |
Pyruvic acid |
- |
- |
- |
[1] 58 |
32 |
Losartan |
Losartan |
D00357, D08146 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[18] 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
33 |
Losartan bluefish 50 mg |
Bluefish, Losartan |
D00357, D08146 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[1] 58 |
34 |
Mangafodipir |
Mangafodipir |
D08262 |
- |
- |
[2] 13, 58 |
35 |
Mavacamten |
Mavacamten |
- |
- |
- |
[1] 58 |
36 |
Mek162 |
- |
- |
- |
- |
[2] 58, 195 |
37 |
Metoprolol |
Metoprolol |
D00601, D02358, D05011 |
[1] ADRB1 |
[10] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
[6] 17, 57, 58, 113, 193, 226 |
38 |
Metoprolol succinate |
Metoprolol |
D00601, D02358, D05011 |
[1] ADRB1 |
[10] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
[4] 57, 58, 113, 193 |
39 |
Midodrine |
Midodrine |
D01307, D08220 |
[3] ADRA1A, ADRA1B, ADRA1D |
[7] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[3] 6, 17, 58 |
40 |
Midodrine hydrochloride |
Midodrine |
D01307, D08220 |
[3] ADRA1A, ADRA1B, ADRA1D |
[7] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[1] 58 |
41 |
Monitor |
Methamidophos |
- |
- |
- |
[12] 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
42 |
Myk-461 |
- |
- |
- |
- |
[1] 58 |
43 |
N-acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
[10] 6, 13, 19, 20, 49, 58, 85, 111, 164, 299 |
44 |
Nitrate |
Nitrate |
D02313 |
- |
- |
[3] 58, 113, 299 |
45 |
Perhexiline |
Perhexiline |
D05442, D08340 |
[8] CACNA1C, CACNA1D, CACNA1F, CACNA1S, CPT1A, CPT1B, CPT1C, CPT2 |
[42] AMPK signaling pathway, Adipocytokine signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, Fatty acid degradation, Fatty acid metabolism, GABAergic synapse, Glucagon signaling pathway, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, PPAR signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Thermogenesis, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[2] 58, 272 |
46 |
Perxexiline |
- |
- |
- |
- |
[1] 58 |
47 |
Pexsig |
- |
- |
- |
- |
[1] 58 |
48 |
Piperazine |
Piperazine |
D00807, D01393, D02127, D02145, D05486, D06224 |
- |
- |
[1] 58 |
49 |
Pirfenidone |
Pirfenidone |
D01583 |
[6] CCL2, IL10, IL1A, IL1B, IL6, TNF |
[80] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[10] 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
50 |
Pyruvate |
Pyruvic acid |
- |
- |
- |
[2] 58, 299 |
51 |
Ranexa |
Ranolazine |
D05700, D05701 |
- |
- |
[1] 58 |
52 |
Ranolazine |
Ranolazine |
D05700, D05701 |
- |
- |
[6] 2, 58, 86, 113, 114, 130 |
53 |
Ranolazine 1000 mg pr tablets |
Ranolazine |
D05700, D05701 |
- |
- |
[1] 58 |
54 |
Ranolazine 500 mg pr tablets |
Ranolazine |
D05700, D05701 |
- |
- |
[1] 58 |
55 |
Ranolazine 750 mg pr tablets |
Ranolazine |
D05700, D05701 |
- |
- |
[1] 58 |
56 |
Ranolazine pr (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die |
Ranolazine |
D05700, D05701 |
- |
- |
[1] 58 |
57 |
Regadenoson |
Regadenoson |
D05711 |
[1] ADORA2A |
[7] Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
[1] 58 |
58 |
Sacubitril |
Sacubitril |
D10225 |
[1] MME |
[4] Alzheimer disease, Hematopoietic cell lineage, Protein digestion and absorption, Renin-angiotensin system |
[1] 58 |
59 |
Sacubitril/valsartan |
Sacubitril |
D10225 |
[1] MME |
[4] Alzheimer disease, Hematopoietic cell lineage, Protein digestion and absorption, Renin-angiotensin system |
[1] 58 |
60 |
Sodium nitrate |
Nitrate |
D02313 |
- |
- |
[2] 58, 113 |
61 |
Spironolactone |
Spironolactone |
D00443 |
[1] NR3C2 |
[1] Aldosterone-regulated sodium reabsorption |
[6] 58, 67, 86, 113, 218, 225 |
62 |
Treatment bx1514m |
- |
- |
- |
- |
[1] 58 |
63 |
Trientine |
Triethylenetetramine |
- |
- |
- |
[2] 58, 171 |
64 |
Trientine dihydrochloride |
Triethylenetetramine |
- |
- |
- |
[2] 58, 171 |
65 |
Trimetazidine |
Trimetazidine |
D01606, D08642 |
- |
- |
[2] 58, 86 |
66 |
Trimetazidine dihydrochloride |
Trimetazidine |
D01606, D08642 |
- |
- |
[1] 58 |
67 |
Trimetazidine dihydrochloride 20mg |
Trimetazidine |
D01606, D08642 |
- |
- |
[1] 58 |
68 |
Valsartan |
Valsartan |
D00400 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[6] 57, 58, 66, 75, 218, 222 |
69 |
Vastarel |
Trimetazidine |
D01606, D08642 |
- |
- |
[1] 58 |
70 |
Vastarel 20mg film coated tablets |
Trimetazidine |
D01606, D08642 |
- |
- |
[1] 58 |